focus -WSS

focus

author：hotspot 2025-08-23 08:57:36 - browse：339

RHONA WISE/AFP via Getty Images

WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new obesity drugs, and they might get some government help. The agency that regulates Obamacare insurance is considering a technical change that would require insurers to cover obesity drugs in a market of more than 20 million Americans.

Weight loss drugs are a blessing for patients, a boon for drugmakers, and a potentially huge expense for insurers and taxpayers. Insurers have been slow to cover the drugs, called GLP-1 agonists, and without insurance, it costs upward of $16,000 annually for a drug that must be taken indefinitely.

There is a lot of demand for the drugs, but there are barriers to coverage. Medicare by law is prohibited from paying for obesity drugs. State Medicaid programs don’t have to cover them, so most don’t.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Wellcome Trust names Røttingen as its new CEO

focus

hotspot

WSS

FDA advisers back CAR

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Life sciences deals on track to hit lowest point since 2017

Female surgeons have lower rates of long

FDA advisers back CAR

Medicare to cover more brain scans related to Alzheimer’s drugs

knowledge

focus

focus

Heart attack and stroke risk calculators need revising

A revolution in caring for preterm infants

BioMarin wins approval for gene therapy to treat hemophilia A

Takeaways from AdvaMed, the largest medical devices conference

The high cost of giving birth even with insurance

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Hepatitis C has a cure — but many Americans still lack access to it

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Hepatitis C has a cure — but many Americans still lack access to it

Life sciences deals on track to hit lowest point since 2017

hotspot

Readout LOUD podcast: Merger Mondays, Ozempic panic

Takeaways from AdvaMed, the largest medical devices conference

Readout Newsletter: CAR

A revolution in caring for preterm infants

European regulators recommend Amylyx's ALS drug be rejected

Change Healthcare outage fallout shows need for new oversight

hotspot

focus

hotspot

hotspot